Alaunos Therapeutics (TCRT) Profit After Tax (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Profit After Tax data on file, last reported at -$1.0 million in Q1 2026.

• Quarterly Profit After Tax rose 6.24% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (down 0.93% YoY) and the FY2025 annual result came in at -$4.2 million, up 10.75% from the prior year.
• Profit After Tax eased to -$1.0 million in Q1 2026, from -$893000.0 in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $22.6 million in Q4 2023 to a low of -$10.0 million in Q1 2023.
• A 5-year average of -$3.1 million and a median of -$1.2 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax surged 346.95% — and 2024, when it sank 103.28%.
• Tracing TCRT's Profit After Tax over 5 years: stood at -$9.2 million in 2022, then soared by 346.95% to $22.6 million in 2023, then sank by 103.28% to -$742000.0 in 2024, then fell by 20.35% to -$893000.0 in 2025, then retreated by 12.65% to -$1.0 million in 2026.
• The last three Profit After Tax figures came in at -$1.0 million (Q1 2026), -$893000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.